Nerve-on-Chips

Projektinformationen

NOC

ID Finanzhilfevereinbarung: 743909

DOI

10.3030/743909

Projekt abgeschlossen

EK-Unterschriftsdatum 7 Dezember 2016

Startdatum 1 Dezember 2016

Enddatum 31 Mai 2017

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

MICROBRAIN BIOTECH
France

Periodic Reporting for period 1 - NOC (Nerve-on-Chips)

Berichtszeitraum: 2016-12-01 bis 2017-05-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Neurodegenerative diseases (hereafter “ND”) are devastating as they cause individuals to lose their memories, independence, and ultimately, their lives. In the absence of drugs able to cureor prevent start of ND, the latter are a human and financial burden for individual patients, their relativesthe health care system and society in general. The worldwide economic impact of ND is evaluated at $2 trillion a year. The incidence of ND is expected to grow in the coming few years as life expectancy increases. In 2020, over 65 million people will suffer from Alzheimer Disease worldwide (over 6.5 million in the EU).

MicroBrain Biotech is an innovative biotech startup founded in 2014. MBBT aims at offering “turn-key solutions” to biopharmaceutical research which will take the shape of microfluidic chips offering different types of reconstructed neuron networks at the micron scale. These chips are called Nerve-on-Chips (hereafter “NoC”, subcategory of Organ-on-Chips), and they simulate the function of tissues and organ subunits.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

A legal feasibility study ensured freedom to operate.

A Business and market analysis allowed us to get in-depth knowledge of the challenges linked to drug discovery, the Organ-on-Chip (OOC) market and the OOC ecosystem, stakeholders, and competitors.

Microfabrication-based methods have been validated to guide network self-assembly, accomplishing control over in vitro circuit size and connectivity. The general goal was to define the best technological opportunities in terms of microfabrication, biological validation, and screening.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Our patented NOC technology provides many advantages over other in vitro models such as conventional two-dimensional (2D) and tri-dimensional (3D) culture systems, over organoids, and over animal models:

- Reduce biopharmaceutical R&D costs and increased efficiency in clinical research (improved competitiveness)
- Reduce animal testing
- Predicting human-relevant drug responses
- Compatibility with readouts used in biology
- Reconstitution of complex organ-level physiological functions- Real-time visualization

NOC will allow to reduce drug R&D costs by 15% which will generate a total turnover worth €30 million. MBBT’s objective is to reach a €2 million worth turnover (i.e.: 8% OOC market share) within the 3 next years. The feasibility study allowed us to ensure IP policy (improvement patent, purchase of licenses) while assessing the market (supply chain, drug agencies, competitors, clients…) and validating the technological and biological approach.

logo-mbbt.png